## **IMMUNOTERAPIA NEL LINFOMA DI HODGKIN:** CHE RUOLO HA OGGI ?

Dott. Gerardo Musuraca

#### Faenza 07/06/2018



## **GHSG Risk Allocation for HL**

	Stage (Ann Arbor)				
<b>Risk factors</b>	IA, IB, IIA	IIB	IIIA, IIIB	IVA, IVB	
None	Early favo	rable			
≥ 3 LK- Areas			Advanced		
Elevated ESR	Early				
Large Med Mass	unfavor- able				
Extranodal disease					

## EARLY STAGE: CHEMO+/-RT:

-PFS rates 3-5 years 82%-94%

## **ADVANCED STAGE:** (ABVD, BEACOPP, STANFORD V)

-PFS rates 5 years 71%-86.4%

Gordon et al J Clin Oncol 2013 Engert et al J Clin Oncol 2009 Borchmann P et al J Clin Oncol 2011 Eich Ht et al J Clin Oncol 2010 Engert A et al N Eng J Med 2010 Radford J et al N Eng J Med 2015

# AUTOLOGOUS FOR RELAPSED/REFRACTORY DISEASE:


## -PFS rates for RELAPSED: 50%-60%

## -PFS rates for REFRACTORY: 40%-50%

## About 50% Relapsed after autologous

Kewalramni et al Bone Marrow Transplant 2003 Hahn et al Biol Blood Marrow Transplant 2013 Schmitz et al Lancet 2002 Ferme' et al J Clin Oncol 2002 Gerrie et al Ann oncol 2014

Survival in Hodgkin Lymphoma Relapse After Autologous HSCT



auto-HSCT = autologous hematopoietic stem cell transplant

# WHO IS THE RELAPSED/REFRACTORY PATIENT ?


#### **Biological Prognostic Factors Reported to Influence Hodgkin Lymphoma Outcome**

Factor	Impact on prognosis
Assessment of Hodgkin-Reed Sternberg cells	
aberrant T-cell antigen expression, IHC/HRS	negative
FOXP3 expression, IHC/HRS	negative
CD20 expression, IHC/HRS	negative
BCL-XL, IHC/HRS	negative
p53, IHC/HRS	negative
HLA class II, IHC/HRS, loss	negative
presence of Epstein-Barr virus (EBV)	negative
Assessment of microenvironmental or circulating non-neoplastic cells, c	ytokines and membrane associated antigens
fibroblast growth factor 2, IHC/circ	negative
syndecan-1, IHC/circ	negative
tumor-associated macrophages, IHC/TM	negative
CD68 expression, IHC/TM	negative
serum TARC, elevated	negative
serum galectin-1, elevated	negative
serum CD163, elevated	negative
serum IL-10, elevated	negative
serum IL-10 receptor, elevated	negative
serum IL-6, elevated	negative
serum CD30, elevated	negative
serum tumor necrosis factor (TNF), elevated	negative
serum TNF receptor, elevated	negative
serum CD4, elevated	negative
serum CD8, elevated	negative
serum CD25, elevated	negative
serum CD54, elevated	negative
Gene expression and miRNA profiling reflecting the tumor microenvironn	ment
gene expression profiling	positive or negative
global microRNA levels including MIR21, MIR30E, MIR30D and MIR92B	positive or negative
	Positive et negative
Host germline polymorphisms and mutations	
IL-10 specific polymorphism 592AA	negative
IL-6 specific polymorphism 174GG Presented By Joseph Connors at 2018 ASC	negative

## International Prognostic Factors Project on Advanced Hodgkin Lymphoma

Factor	Criteria in SI units		
Age	> 44 y		
Gender	male		
Stage	IV		
Albumin	< 40 g/L		
WBC	> 15 x 10 <sup>9</sup> /L		
Hemoglobin	< 105 g/L		
Lymphs	< 0.6 x 10 <sup>9</sup> /L or		
	< 8%		

Hasenclever. N Engl J Med. 1998;339:1506



adapted from Biggi. J Nucl Med. 2013;54:683.

Presented By Joseph Connors at 2018 ASCO Annual Meeting

## **RISK FACTORS FOR RELAPSE AFTER AUTOLOGOUS:**

#### -NUMBER OF PRIOR REGIMENS

#### -LESS THAN A PET CR BEFORE ASCT

#### -DURATION OF FIRST REMISSION < 12 MONTHS

-Karnofsky< 90

-EXTRANODAL INVOLVEMENT

Spaepen et al Blood 2003 Hahn et al Biol Blood Marrow Transplant 2013

## Modern Immunotherapy Approaches to Lymphoma

## Antigen Specific Anti-tumor Immunotherapy

## Antigen Independent Antitumor Immunotherapy

# 

#### Abramson ASCO 2018

#### Advani et al ASCO 2018 7504




2018 ASCO ANNUAL MEETING MANUAL MEETING

PRESENTED BY: Caron Jacobson, MD MMSc

http://clicktoeditURL.com

#### **BRENTUXIMAB VEDOTIN (SGN-35) : MECHANISM OF ACTION**



## SGN35-003: 5-year follow-up from phase II study of brentuximab vedotin in R/R HL post-ASCT – Update *Blood* 2016(NCT00848926)

**Endpoints:** *Primary*: ORR (IFR); *Secondary:* CR rate, DOR, PFS, OS, safety **Patients:** 102 pts with R/R CD30+ HL after ASCT; median age 31 yrs (15–77), median of 3.5 (1–13) prior chemotherapy regimens, 71% refractory to frontline therapy, 42% refractory to most recent treatment, 71% relapsed ≤1 yr post-ASCT


#### **Dose and Schedule:**



- All pts completed treatment Aug 2010, and were followed for PD/OS until end of study
  - Follow-up: every 3 mos for 2 yrs; every 6 mos yrs 3–5; every 12 months thereafter

**Efficacy:** Median observation time from first dose at study closure (~5 yrs after EOT visit for last pt) was 35.1 mos (1.8–72.9)

#### **Brentuximab Vedotin Active in Relapsed HL**




Younes, et al. J Clin Oncol. 2012; 30(18): 2183-2189.

Presented By Catherine Magid Diefenbach at 2018 ASCO Annual Meeting


## SGN35-003: 5-year follow-up from phase II study of brentuximab vedotin in R/R HL post-ASCT – Update *Blood* 2016(NCT00848926)

Efficacy (cont'd): ORR: 72%; CR rate: 33% (per investigator)



Gopal AK, et al. Blood 2015;125:1236-43

## **Brentuximab Vedotin in Relapsed/Refractory HL**



## SGN35-003: 5-year follow-up from phase II study of brentuximab vedotin in R/R HL post-ASCT<sup>1</sup> – Update *Blood* 2016(NCT00848926)

Safety: Pts received a median of 9 cycles (1–16) of brentuximab vedotin

 Gr ≥3 AE in ≥5% of pts were 20% neutropenia, 8% sensory PN, 8% thrombocytopenia, 6% anemia

Reason for treatment discontinuation, n (%)*	CR (n=34)	PR (n=39)	
Completed treatment	12 (35)	4 (10)	
PD	4 (12)	23 (59)	
AE	9 (26)	5 (13)	
Investigator decision	7 (21)	4 (10)	
Pt decision	2 (6) 3 (8)		
Treatment-emergent PN	N=	:102	
Pts experiencing PN, n (%)	56 (55%)		
PN outcome, %	n=56		
Complete resolution	73%		
Improvement	14%		
Ongoing PN Gr ≤2 at last follow-up, n (%)	15 (27%)		
Grade ≥3 PN at last follow-up	0		

Chen R, et al. Blood 2016

Previous publications: Chen R, et al. ASH 2015, Poster presentation from Abstract #2736

Younes A, et al. J Clin Oncol 2012;30:2183-9;

Gopal AK, et al. Blood 2015;125:1236-43

\*1 patient was not evaluable for response

## SALVAGE BEFORE TRANSPLANT

#### Single Agent BV in Second Line Salvage: Response Rate

	Best response to BV, N=37	Response to combination chemothera py (ICE/DICE/I GEV/GND) post-BV, N=18	Disease Status at AHCT, N=33	
ORR	25/37 (68%)	16/18 (89%)		
CR	13/37 (35%)	11/18 (61%)	24/33 (73%)	
PR	12/37 (32%)	5/18 (28%)	9/33 (27%)	
SD	10/37 (27%)	1/18 (6%)	1/33 (3%)	
PD	2/37 (5%)	1/18 (6%)		

Chen et al. Biol Blood Marrow Transplant. 2015 Dec; 21(12): 2136-2140




Presented By Catherine Magid Diefenbach at 2018 ASCO Annual Meeting

## SALVAGE BEFORE TRANSPLANT

## SGN35-016: Phase I/II trial of brentuximab vedotin combined with bendamustine in R/R HL: updated 2-yr results (NCT01874054)

Study Design:



#### **TREATMENT (21-day cycles)**

**Safety:** Median 2 cycles (1–6) of brentuximab vedotin 1.8 mg/kg + bendamustine 90 mg/m<sup>2</sup>, median 10 cycles (1–14) of single-agent brentuximab vedotin (n=31; 25 ASCT pts, 6 non-ASCT pts). 3 pts died, due to progression of HL (2 pts) or septic shock after transplant (1 pt)

- IRRs were observed in 58% of pts overall, most common symptoms (≥15%) were pyrexia, chills, dyspnea, flushing, and nausea
- Protocol was amended to require premedication with corticosteroids and antihistamines, the use of which decreased the severity of IRRs:

Toxicity, %	Pre-amendment n=25	Post-amendment n=30
Discontinuation	24	7
SAE	24	10
Gr≥3	32	17


LaCasce et al, ISHL 2016 Poster #P020, Updated from LaCasce et al, ASH 2014, Abstract #293

## SALVAGE BEFORE TRANSPLANT

SGN35-016: Phase I/II trial of brentuximab vedotin combined with bendamustine in R/R HL: updated 2-yr results (NCT01874054)

Response (Cont'd): Median follow-up: ~23 mos from first dose (N=53), 21 mos from ASCT (n=40)

#### OS – all patients and ASCT subset



Overall estimated 24-month


- All pts: 63% (95% CI: 46, 76)
- ASCT: 70% (95% CI: 51, 83)
- 93% (13/14) of pts observed for ≥24 mos remain

LaCasce et al, ISHL 2016 Poster #P020, Updated from LaCasce et al, ASH 2014, Abstract #293

## **CONSOLIDATION POST ASCT**

## Aethera Study Design and Key Eligibility Criteria


• 329 patients were randomized at 78 sites in North America and Europe



Moskowitz. Lancet. 2015;385:1853.

## **CONSOLIDATION POST ASCT**

#### PFS per Investigator—3 Years Since Last Patient Randomized




\*Includes clinical assessments of lymphoma.

Moskowitz. Lancet. 2015;385:1853. Updated Lugano ICML 2017

## FIRST LINE

ECHELON-1: Open-label, global, randomized, phase 3 study of A+AVD versus ABVD in patients with newly diagnosed advanced cHL




cHL, classic Hodgkin lymphoma; ECOG PS, Eastern Cooperative Oncology Group performance status; EOT, end-oftreatment; PFS, progression-free survival

Connors. N Engl J Med 2018;378:331.

## FIRST LINE


#### **Modified PFS per investigator**



Connors. N Engl J Med 2018;378:331.


## FIRST LINE

Impact of A-AVD vs ABVD on mPFS: PET2 neg vs PET2 pos



Chen. ASCO 2018, abstract 7539, poster Monday 4 June 2018

## Nivolumab and Ipilimumab Mechanism of Action



4. Wang C et al. Cancer Immunol Res 2014;2:1-11

VYU Langone Health

Presented By Catherine Magid Diefenbach at 2018 ASCO Annual Meeting

Immunomodifiers in Lymphoma Selection

Antibody	Target	Company
Nivolumab	PD1	BMS
Pembrolizumab	PD1	MSD
REGN2810	PD1	Regeneron
Durvalumab	PD-L1	Celgene
Avelumab	PD-L1	Pfizer
Ipilimumab	CTLA-4	BMS

#### Results of PD1 Blocking Antibodies in Relapsed HL Results of Phase-II Studies

#### **Post ASCT and Brentuximab Vedotin**

Drug	Dose/Schedule	N	% ORR	% CR	1 <sup>st</sup> Author/Ref
Pembrolizumab (humanized IgG4)	200 mg IV Q 3wks	69	72%	21%	Chen, R & C. Moskowitz JCO 2017
Nivolumab (Fully human IgG4)	3 mg/kg IV Q 2 wks	80	66%	9%	Younes, A/Lancet Oncology 2016


#### **Results of PD1 Blocking Antibodies in Relapsed HL** Results of Phase-II Studies

#### Post ASCT but No PRIOR Brentuximab Vedotin

Drug	Dose/Schedule	N	% ORR	% CR	1 <sup>st</sup> Author/Ref
Pembrolizumab (humanized IgG4)	200 mg IV Q 3wks	60	67%	21%	Chen, R & C. Moskowitz JCO 2017
Nivolumab (Fully human IgG4)	3 mg/kg IV Q 2 wks	63	68%	22%	Fanale, M/ ICML2017

#### Phase 2 CheckMate 205 Study Design





CR = complete response; DOR = duration of response; IRC = Independent Radiology Review Committee; ORR = objective response rate; OS = overall survival; PFS = progression-free survival; PR = partial response; Q2W = every 2 weeks.

Phase 2 CheckMate 205 Best Overall Response

**BV** naïve **BV** before and/or Overall BV after auto-HSCT after auto-HSCT (Cohort A) (Cohort B) (Cohort C) n = 100n = 243n = 63n = 80Objective resp.<sup>a</sup> % (95% CI) 65 (52, 77) 68 (56, 78) 73 (63, 81) 69 (63, 75) Best overall response, % Complete remission<sup>b</sup> 29 13 12 16 Partial remission 37 55 61 53 Stable disease 24 21 15 19 **Progressive disease** 11 8 10 9 Unable to determine 2 0 4 2

Per investigator assessment, 33% pts achieved CR and 39% PR

<sup>a</sup>Defined according to 2007 International Working Group criteria. Responses were assessed by IRC; <sup>b</sup>All CRs




#### Phase 2 CheckMate 205 Safety Outcomes after Extended Follow-up



Patients with drug-related AEs (≥10%), serious AEs (≥1%), or AEs leading to discontinuation (≥1%)	Overall population n = 243		
Drug-related AEs, %	Any grade	Grade 3-4	
Fatigue	23	1	
Diarrhea	15	1	
Infusion-related reaction	14	<1	
Rash	12	1	
Drug-related serious AEs, %		1	
Infusion-related reaction	2	<1	
Pneumonitis	1	0	
Drug-related AEs leading to discontinuation, %		1	
Pneumonitis	2	0	
Autoimmune hepatitis	1	1	

Phase 2 CheckMate 205 PFS by Best Overall Response



Median (95% CI) PFS for overall patients (N = 243) was 15 (11, 19) months


Engert et al, EHA 2017

www.ghsg.org

0


www.ghsg.org

Phase 2 CheckMate 205 Overall Survival



All values are medians (95% CI). NR = not reached

	Cohort A	Cohort B	Cohort C	Overall
12-month OS, %	93 (83-98)	95 (87-98)	90 (82-94)	92 (88-95)




At database lock (October 2017), median duration of follow-up was 11.1 months.

Bleomycin excluded due to potential overlapping pulmonary toxicity.

1. Ramchandren R et al. Blood. 2017;130:Abstract 651.

#### **Response per IRC and Investigator: ITT Population<sup>1</sup>**



At end of therapy, ORR per investigator for the ITT population was 84%, with 80% of patients achieving CR
 Five patients were nonevaluable at end of therapy<sup>a</sup>

<sup>a</sup> No evaluable scan in at least one on-study time point.

Biopsies were not required for patients to be considered to have progressive disease.

Values may not add together due to rounding.


1. Ramchandren R et al. Blood. 2017;130:Abstract 651.

### CHECKPOINT INHIBITORS

14th International Conference on Malignant Lymphoma; June 14-17, 2017

#### Avelumab

- Human anti–PD-L1 IgG1 mAb
- Inhibits PD-L1/PD-1 interactions,<sup>1</sup>
  leaving PD-L2/PD-1 pathway intact
  - Unlike anti–PD-1antibodies that target T cells, avelumab targets tumor cells
- Half-life ≈4 days; >90% target occupancy dosing Q2W at 10 mg/kg<sup>1</sup>
- Induces ADCC against tumor cells in vitro<sup>2,3</sup>
- Antitumor activity in lung, bladder, renal, and other malignancies<sup>4-6</sup>
- FDA-approved treatment for metastatic Merkel cell carcinoma and advanced urothelial carcinoma progressed after platinum-containing chemotherapy<sup>7</sup>




### CHECKPOINT INHIBITORS

14th International Conference on Malignant Lymphoma; June 14-17, 2017

#### Study design: JAVELIN Hodgkin (NCT02603419)

Phase 1b, open-label, multicenter, multiple-dose, randomized, parallel-arm trial



Data cutoff date for this presentation: April 21, 2017

allo, allogeneic; auto, autologous; cHL, classical Hodgkin lymphoma; IV, intravenous; NCI CTCAE, National Cancer Institute Common Terminology Criteria for Adverse Events; R, randomize; Q2W, every 2 weeks; Q3W, every 3 weeks; SCT, stem cell transplant. \* Per NCI CTCAE v4.03.

1. Cheson BD, et al. J Clin Oncol. 2007;25(5):579-86.

### CHECKPOINT INHIBITORS

14th International Conference on Malignant Lymphoma; June 14-17, 2017

#### **Best overall response**


- ORR was 41.9%, including CR in 16.1% and PR in 25.8%
- Median time to response was 1.5 months (range 1.4-6.2)

BOR n (%)	Overall population N=31
CR	5 (16.1)
PR	8 (25.8)
SD	9 (29.0)
PD	5 (16.1)
NE*	4 (12.9)
ORR, %	41.9
DCR, %	71.0


BOR, best overall response; CR, complete response; DCR, disease control rate; NE, not evaluable; ORR, objective response rate; PD, progressive disease; PR, partial response; SD, stable disease.

\* Patients had no post-baseline assessments for reasons other than death.

#### Nivolumab + Brentuximab Salavage Therapy for HL



#### **PFS and OS BV+ Nivo**






### **BV + /- Ipilimumab is Highly Active**

**BV + IPI 21 Response Eligible Patients** 


Evaluabl e Pts.	ORR	CR	PR	SD	IE* for Respons e	PD
N = 21	16 (76%)	10 (48%)	6 (29%)	2 (10%)	1 (5%)	2 (10%)



**NYULangone** 

Health

#### PFS and OS Arms BV + Ipi





27

PFS

NYU Langone Health

Presented By Catherine Magid Diefenbach at 2018 ASCO Annual Meeting

reached

0.74 - -)


## IMMUNOTHERAPY

# WHAT' S THE RIGHT ALGORITM?

## WHAT'S THE RIGHT LINE?

(First? Salvage?After ASCT?

Bridge to Allo?)



COULD YOU STRATIFY PATIENTS BASED ON RISK OR ON BIOLOGY?



Presented By Catherine Magid Diefenbach at 2018 ASCO Annual Meeting



HODGKIN DISEASE IS HIGHLY CURABLE DISEASE WITH CHEMOTHERAPY.

HOWEVER SOME PATIENTS ARE PRIMARY REFRACTORY OR RELAPSE AFTER FIRST LINE THERAPY OR ASCT

ASCT LEADS TO 3 YEARS PFS RATE OF 40%TO 60 % ACCORDING TO REFRACTORY OR RELAPSE PATIENTS

MEDIAN OS AFTER ASCT RELAPSE WAS 1 TO 2 YEARS


## CONCLUSIONS

NEW AGENTS ARE CHANGING THE HYSTORY OF THE DISEASE

AND NOW PROBABLY THE INDICATION TO ALLO WILL BE CONTROVERSIAL IN CHECKPOINT INHIBITORS ERA, IN RELAPSED PATIENTS AFTER AUTO.

THE TREATMENT ALGORITHM IS RAPIDLY CHANGING TOWARD A COMBO THERAPY WITH IMMUNO AND CHEMOTHERAPY OR IMMUNOTHERAPY ALONE.

### Brief History of Immunotherapy in Oncology



# GRAZIE PER L'ATTENZIONE

